A Phase 2/3 interventional study of aflibercept and High-dose aflibercept in Diabetic Macular Edema, Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus, sponsored by Regeneron Pharmaceuticals. Completed at 138 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 31st largest by enrollment of the 1,242 interventional ones that give a count, is one of 71 that started in 2020, is one of 20 in phase 2/3, and was the 1,037th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Wayne State University · Sites in United States
Ages 16–20
Medtronic MiniMed, Inc. · Sites in United States
Ages 2–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 71 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 660 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 64 across the 203 observational. Of the 1,117 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
117 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 117 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks.
The secondary objectives of the study are as follows:
Key Inclusion Criteria:
Extension Phase: All randomized patients that complete visit 26, week 96, as long as the patient 1) provides informed consent and 2) no treatment for DME has been given in the study eye other than the randomized study treatment.
Key Exclusion Criteria:
NOTE: Other Protocol Defined Inclusion/Exclusion Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered every 8 weeks after a loading phase
Drug: aflibercept
Administered every 12 weeks after a loading phase
Drug: High-dose aflibercept
Administered every 16 weeks after a loading phase
Drug: High-dose aflibercept
Intravitreally (IVT) administered as a liquid formulation in a vial
Also known as: EYLEA®, BAY86-5321
Intravitreally (IVT) administered as a liquid formulation in a vial
Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).
Time frame: Baseline, Week 48
Percentage of Participants With a ≥2 Step Improvement From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Score at Week 48
The DRSS was assessed according to the following scale: 10 = Diabetic retinopathy (DR) absent, 14 = DR questionable, 15 = DR questionable, 20 = Micro-aneurysms only, 35 = Mild Non-proliferative diabetic retinopathy (NPDR), 43 = Moderate NPDR, 47 = Moderately severe NPDR, 53 = Severe NPDR, 61 = Mild Proliferative diabetic retinopathy (PDR), 65 = Moderate PDR, 71 = High-risk PDR, 75 = High-risk PDR, 81 = Advanced PDR: fundus partially obscured, center of macula attached, 85 = Advanced PDR: posterior fundus obscured, or center of macula detached, 90 = cannot grade, even sufficiently for level 81 or 85.
Time frame: Baseline, Week 48
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline at Week 48
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). Only one study eye per participant was analyzed within the study
Time frame: Baseline, Week 48
Percentage of Participants With BCVA ≥69 Letters at Week 48
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).
Time frame: At Week 48
Percentage of Participants Without Fluid at Foveal Center at Week 48
Retinal fluid status was evaluated using spectral domain optical coherence tomography (SD-OCT) on the study eye.
Time frame: At Week 48
Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 48
Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).
Time frame: Baseline, Week 48
Percentage of Participants Without Leakage on Fluorescein Angiography (FA) at Week 48
Leakage is the release of fluorescein dye from diseased retinal vessels.
Time frame: At Week 48
Change From Baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Total Score at Week 48
Vision-specific quality of life is assessed with the NEI VFQ-25 (National Eye Institute Visual Function Questionnaire), i.e. a 25-item questionnaire that gives a score on a scale from 0 (worst) to 100 (best = no vision problems).
Time frame: Baseline, Week 48
Systemic Pharmacokinetics (PK) of Aflibercept as Assessed by Plasma Concentrations Through Week 48
Concentrations of Free Aflibercept in Plasma by Time and Treatment Group
Time frame: Through Week 48
Change From Baseline in BCVA in the Study Eye in Participants With Both Baseline and Week 48 BCVA
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per Statistical Analysis Plan (SAP) Version 2.0 Appendix 10.9 for US Only)
Time frame: Baseline, Week 48
Change From 8-weeks Post Initial Treatment Phase in BCVA in the Study Eye in Participants With Both 8-weeks Post Initial Treatment Phase BCVA and Week 48 BCVA
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per SAP Version 2.0 Appendix 10.9 for US Only)
Time frame: Baseline, Week 48
Change From Baseline in BCVA (Region-specific Analysis) in the Study Eye at Week 60
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).
Time frame: Baseline, Week 60
Assessment of Immunogenicity to Aflibercept by Measuring the Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response Through Week 96
Number of participants with pre-existing immunoreactivity and treatment-emergent ADA response reported
Time frame: Through Week 96
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Through Week 96
A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent.
Time frame: Through Week 96
Number of Participants With Any Serious TEAE Through Week 96
A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent.
Time frame: Through Week 96
Number of Participants With Any TEAE Through Week 156
TEAEs are defined as AEs starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days or week 156 visit, whichever was later.
Time frame: Through Week 156
Number of Participants With Any Serious TEAE Through Week 156
Time frame: Through Week 156
| Milestone | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) | 2q8/HD Aflibercept (Extension) | HDq12 Aflibercept (Extension) | HDq16 Aflibercept (Extension) |
|---|---|---|---|---|---|---|
| Started | 167 | 329 | 164 | 0 | 0 | 0 |
| Treated | 167 | 328 | 163 | 0 | 0 | 0 |
| Completed week 48 | 157 | 300 | 156 | 0 | 0 | 0 |
| Completed week 60 | 155 | 289 | 152 | 0 | 0 | 0 |
| Completed | 139 | 256 | 139 | 0 | 0 | 0 |
| Not completed | 28 | 73 | 25 | 0 | 0 | 0 |
| Withdrew: Non-compliance with protocol by the subject | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 9 | 2 | 0 | 0 | 0 |
| Withdrew: Decision by the investigator/sponsor | 2 | 9 | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 17 | 8 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 19 | 7 | 0 | 0 | 0 |
| Withdrew: Death | 9 | 18 | 5 | 0 | 0 | 0 |
| Milestone | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) | 2q8/HD Aflibercept (Extension) | HDq12 Aflibercept (Extension) | HDq16 Aflibercept (Extension) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 70 | 130 | 65 |
| Completed | 0 | 0 | 0 | 58 | 103 | 49 |
| Not completed | 0 | 0 | 0 | 12 | 27 | 16 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Decision by the investigator/sponsor | 0 | 0 | 0 | 0 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 5 | 10 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 3 | 6 | 6 |
| Withdrew: Death | 0 | 0 | 0 | 2 | 7 | 2 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).
| Letters | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48 | 8.67 ± 0.73 | 8.10 ± 0.61 | 7.23 ± 0.71 |
The DRSS was assessed according to the following scale: 10 = Diabetic retinopathy (DR) absent, 14 = DR questionable, 15 = DR questionable, 20 = Micro-aneurysms only, 35 = Mild Non-proliferative diabetic retinopathy (NPDR), 43 = Moderate NPDR, 47 = Moderately severe NPDR, 53 = Severe NPDR, 61 = Mild Proliferative diabetic retinopathy (PDR), 65 = Moderate PDR, 71 = High-risk PDR, 75 = High-risk PDR, 81 = Advanced PDR: fundus partially obscured, center of macula attached, 85 = Advanced PDR: posterior fundus obscured, or center of macula detached, 90 = cannot grade, even sufficiently for level 81 or 85.
| Percentage of Participants | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Percentage of Participants With a ≥2 Step Improvement From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Score at Week 48 | 26.6 | 29.0 | 19.6 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). Only one study eye per participant was analyzed within the study
| Percentage of Participants | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline at Week 48 | 23.0 | 18.7 | 16.6 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).
| Percentage of Participants | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Percentage of Participants With BCVA ≥69 Letters at Week 48 | 63.0 | 65.3 | 62.6 |
Retinal fluid status was evaluated using spectral domain optical coherence tomography (SD-OCT) on the study eye.
| Percentage of Participants | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Percentage of Participants Without Fluid at Foveal Center at Week 48 | 54.5 | 58.5 | 43.8 |
Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).
| Microns | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 48 | -164.85 ± 8.79 | -176.77 ± 5.73 | -148.84 ± 9.45 |
Leakage is the release of fluorescein dye from diseased retinal vessels.
| Percentage of Participants | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Percentage of Participants Without Leakage on Fluorescein Angiography (FA) at Week 48 | 2.5 | 7.6 | 0.7 |
Vision-specific quality of life is assessed with the NEI VFQ-25 (National Eye Institute Visual Function Questionnaire), i.e. a 25-item questionnaire that gives a score on a scale from 0 (worst) to 100 (best = no vision problems).
| Score on a Scale | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Change From Baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Total Score at Week 48 | 2.82 ± 1.10 | 4.06 ± 0.80 | 2.94 ± 0.93 |
Concentrations of Free Aflibercept in Plasma by Time and Treatment Group
| milligram/Litre (mg/L) | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Systemic Pharmacokinetics (PK) of Aflibercept as Assessed by Plasma Concentrations Through Week 48 | 0.00102 ± 0.00580 | 0.0111 ± 0.0157 | 0.00105 ± 0.00477 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per Statistical Analysis Plan (SAP) Version 2.0 Appendix 10.9 for US Only)
| Letters | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Change From Baseline in BCVA in the Study Eye in Participants With Both Baseline and Week 48 BCVA | 9.11 ± 8.94 | 9.14 ± 8.35 | 9.11 ± 7.30 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best). (Per SAP Version 2.0 Appendix 10.9 for US Only)
| Letters | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Change From 8-weeks Post Initial Treatment Phase in BCVA in the Study Eye in Participants With Both 8-weeks Post Initial Treatment Phase BCVA and Week 48 BCVA | 1.63 ± 6.65 | 1.68 ± 5.54 | 1.64 ± 4.75 |
Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).
| Letters | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Change From Baseline in BCVA (Region-specific Analysis) in the Study Eye at Week 60 | 9.40 ± 0.77 | 8.52 ± 0.63 | 7.64 ± 0.75 |
Number of participants with pre-existing immunoreactivity and treatment-emergent ADA response reported
| Participants | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Pre-existing Immunoreactivity | 4 | 11 | 2 |
| Treatment-Emergent | 2 | 7 | 4 |
A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent.
| Participants | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Through Week 96 | 134 | 277 | 143 |
A TEAE is an AE starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days. Additionally, for patients who are still participating in the study (ie, have not been withdrawn and are continuing in the extension phase of the study) as of the week 96 visit all AEs up through the date of the week 96 visit were considered treatment-emergent.
| Participants | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) |
|---|---|---|---|
| Number of Participants With Any Serious TEAE Through Week 96 | 46 | 81 | 44 |
TEAEs are defined as AEs starting after the first dose of study drug to the last dose of study drug (active or sham) plus 30 days or week 156 visit, whichever was later.
| Participants | 2q8/HD Aflibercept (Extension) | HDq12 Aflibercept (Extension) | HDq16 Aflibercept (Extension) |
|---|---|---|---|
| Number of Participants With Any TEAE Through Week 156 | 64 | 122 | 59 |
| Participants | 2q8/HD Aflibercept (Extension) | HDq12 Aflibercept (Extension) | HDq16 Aflibercept (Extension) |
|---|---|---|---|
| Number of Participants With Any Serious TEAE Through Week 156 | 27 | 41 | 22 |
Collected over From first study treatment through week 156. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept 2 mg Every 8 Weeks (2q8) | 9/167 (5.4%) | 46/167 (27.5%) | 98/167 (58.7%) |
| HD Aflibercept Every 12 Weeks (HDq12) | 18/328 (5.5%) | 84/328 (25.6%) | 190/328 (57.9%) |
| HD Aflibercept Every 16 Weeks (HDq16) | 5/163 (3.1%) | 45/163 (27.6%) | 116/163 (71.2%) |
| 2q8/HD Aflibercept (Extension) | 2/70 (2.9%) | 27/70 (38.6%) | 50/70 (71.4%) |
| HDq12 Aflibercept (Extension) | 7/130 (5.4%) | 46/130 (35.4%) | 99/130 (76.2%) |
| HDq16 Aflibercept (Extension) | 3/65 (4.6%) | 23/65 (35.4%) | 50/65 (76.9%) |
| Event | Aflibercept 2 mg Every 8 Weeks (2q8) | HD Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) | 2q8/HD Aflibercept (Extension) | HDq12 Aflibercept (Extension) | HDq16 Aflibercept (Extension) |
|---|---|---|---|---|---|---|
| SepsisInfections and infestations | 4/167 | 2/328 | 0/163 | 3/70 | 1/130 | 0/65 |
| PneumoniaInfections and infestations | 1/167 | 6/328 | 0/163 | 0/70 | 4/130 | 1/65 |
| OsteomyelitisInfections and infestations | 0/167 | 2/328 | 0/163 | 0/70 | 4/130 | 0/65 |
| CellulitisInfections and infestations | 2/167 | 1/328 | 2/163 | 1/70 | 0/130 | 2/65 |
| Myocardial infarctionCardiac disorders | 3/167 | 5/328 | 3/163 | 1/70 | 4/130 | 1/65 |
| Acute kidney injuryRenal and urinary disorders | 2/167 | 7/328 | 1/163 | 1/70 | 4/130 | 0/65 |
| Cerebrovascular accidentNervous system disorders | 0/167 | 3/328 | 5/163 | 1/70 | 3/130 | 2/65 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/167 | 0/328 | 3/163 | 1/70 | 1/130 | 2/65 |
| Diabetic footSkin and subcutaneous tissue disorders | 0/167 | 2/328 | 1/163 | 0/70 | 4/130 | 0/65 |
| Acute myocardial infarctionCardiac disorders | 2/167 | 10/328 | 2/163 | 1/70 | 2/130 | 0/65 |
| Event | Aflibercept 2 mg Every 8 Weeks (2q8) | HD Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) | 2q8/HD Aflibercept (Extension) | HDq12 Aflibercept (Extension) | HDq16 Aflibercept (Extension) |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 15/167 | 40/328 | 26/163 | 6/70 | 19/130 | 15/65 |
| HypertensionVascular disorders | 22/167 | 35/328 | 31/163 | 6/70 | 21/130 | 13/65 |
| Cataract Study EyeEye disorders | 5/167 | 18/328 | 18/163 | 8/70 | 18/130 | 10/65 |
| Cataract Fellow EyeEye disorders | 8/167 | 17/328 | 14/163 | 7/70 | 18/130 | 8/65 |
| NasopharyngitisInfections and infestations | 9/167 | 21/328 | 10/163 | 5/70 | 16/130 | 4/65 |
| InfluenzaInfections and infestations | 6/167 | 5/328 | 3/163 | 5/70 | 5/130 | 7/65 |
| Vitreous haemorrhage Fellow EyeEye disorders | 5/167 | 7/328 | 6/163 | 6/70 | 8/130 | 3/65 |
| Punctate keratitis Study EyeEye disorders | 1/167 | 5/328 | 7/163 | 1/70 | 3/130 | 5/65 |
| Retinal haemorrhage Study EyeEye disorders | 1/167 | 0/328 | 6/163 | 1/70 | 1/130 | 5/65 |
| Vitreous floaters Fellow EyeEye disorders | 4/167 | 4/328 | 8/163 | 2/70 | 3/130 | 5/65 |
Full analysis set (FAS): All randomized participants who received at least 1 dose of study drug; it was based on the treatment assigned to the participant at baseline (as randomized). Only one study eye per participant was analyzed within the study.
| Age, Continuous(Years) | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) | Total |
|---|---|---|---|---|
| Mean | 63.0 ± 9.78 | 62.1 ± 11.13 | 61.9 ± 9.50 | 62.3 ± 10.41 |
| Sex: Female, Male(Participants) | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) | Total |
|---|---|---|---|---|
| Female | 75 | 118 | 64 | 257 |
| Male | 92 | 210 | 99 | 401 |
| Ethnicity (NIH/OMB)(Participants) | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 31 | 54 | 34 | 119 |
| Not Hispanic or Latino | 133 | 266 | 126 | 525 |
| Unknown or Not Reported | 3 | 8 | 3 | 14 |
| Race/Ethnicity, Customized(Participants) | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 2 |
| Asian | 30 | 48 | 23 | 101 |
| Black or African American | 18 | 35 | 9 | 62 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| White | 112 | 231 | 128 | 471 |
| Multiple | 0 | 1 | 0 | 1 |
| Other | 4 | 6 | 1 | 11 |
| Not Reported | 3 | 4 | 2 | 9 |
| Best Corrected Visual Acuity (BCVA) in the Study Eye(Letters) | Aflibercept 2 mg Every 8 Weeks (2q8) | High-dose (HD) Aflibercept Every 12 Weeks (HDq12) | HD Aflibercept Every 16 Weeks (HDq16) | Total |
|---|---|---|---|---|
| Mean | 61.5 ± 11.22 | 63.6 ± 10.10 | 61.4 ± 11.76 | 62.5 ± 10.86 |
Showing the first 100 of 138 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All IPD that underlie results in a publication.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in a manuscript. Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.
Data sharing details ↗ · vivli.org
Ran from Jun 2020 to primary completion in May 2022, 23 months.
Results were first posted in Nov 2023, 1 year 5 months after primary completion. A results delay was requested in May 2023.
Of 19 phase 2/3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept